Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Insulin‑aspart‑szjj bulk supplier for pharma manufacturers

Insulin‑Aspart‑Szjj 100 units/mL Suppliers & Bulk Manufacturers

Available Forms: SQ Injection

Available Strengths: 100 units/mL

Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.

Category: Biosimilars

Merilog, a biosimilar to NovoLog (insulin aspart), mimics natural insulin by stimulating glucose uptake in tissues, reducing blood sugar levels. It provides rapid, consistent blood glucose control, supports flexible dosing, and offers similar efficacy, safety, and benefits as the original, supporting effective diabetes management when used under medical supervision.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Merilog is regulated as a biosimilar to NovoLog (insulin aspart) in both the EU and US. In the US, FDA approval involves extensive comparability, safety, and efficacy data in accordance with GMP standards. In the EU, CE marking certifies conformity with MDR standards for biosimilarity, validated through dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality. These biosimilars undergo validation, stability testing, and audits, supported by comprehensive documentation including clinical data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality insulin biosimilars supporting optimal diabetes management worldwide.

Insulin‑Aspart‑Szjj — third party manufacturing & bulk supply

Insulin‑Aspart‑Szjj 100 units/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Indicative minimum order quantity

Insulin‑Aspart‑Szjj is supplied as SQ Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Insulin‑Aspart‑Szjj listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Insulin‑Aspart‑Szjj →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Insulin‑aspart‑szjj is listed as SQ Injection in 100 units/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Insulin‑aspart‑szjj is referenced against NovoLog; Merilog is biosimilar to NovoLog.. Reference brands are shown for identification only and remain the property of their respective trademark owners.

Insulin‑aspart‑szjj is catalogued under Biosimilars on PharmaTradz. Related products within the same category are listed at the foot of this page.

Submit an RFQ stating your destination market, required quantity and whether you need stock supply, third party manufacturing or dossier licensing. Matched suppliers respond with pricing, MOQ and lead times.

Related Products

Eculizumab‑Aeeb

Strength:
300 mg/20 mL (IV infusion),

Form: Injection for intravenous infusion

Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris

View Details
Omalizumab‑Igec

Strength:
75 mg/0.5 mL and 150 mg/mL

Form: Pre filled syringe

Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair

View Details
Tocilizumab-Bavi

Strength:
80 mg/4ml

Form: Intravenous infusion

Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).

View Details
Denosumab(Others Approved)

Strength:
60 mg, 120 mg

Form: Subcutaneous injection

Reference Brands: Xgeva(US & EU) Ospomyv, Xbryk, Merilog, Stoboclo, Zadenvi, Enwylma, Denbrayce, Izamby - biosimilar to Xgeva

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.